openPR Logo
Press release

Fragile X Syndrome Market 2032, Insights by Delveinsight | Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics

09-11-2024 04:33 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Fragile X Syndrome Market

Fragile X Syndrome Market

The market size of Fragile X Syndrome is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Hoffmann-La Roche

[Nevada, United States] - DelveInsight, a leading market research company, is excited to introduce its newest report, titled "Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast 2032." This innovative report offers a detailed examination of Fragile X Syndrome, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Fragile X Syndrome Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Fragile X Syndrome Market Report:
The Fragile X Syndrome market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In August, 2024: Zynerba Pharmaceuticals, Inc. announced that a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS).
In July, 2024: Spinogenix disclosed that their Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
In January, 2024: Ovid Therapeutics Inc. announced that the purpose of their study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.
The total diagnosed prevalent population of Fragile X Syndrome in the 7MM was estimated to be around ~123,000 in 2023. Additionally, there was a diagnosed prevalent population of ~71,000 cases of FXS in the US.
Among the gender-specific prevalent cases,in 2023, there were nearly ~60% cases of Fragile X Syndrome in males and nearly ~40% cases in females, in the US.
Key Fragile X Syndrome Companies are as follow: Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology
Key Fragile X Syndrome Therapies are as follows: ZYN002, Placebo, SPG601, OV101 (gaboxadol), BPN14770/ zatolmilast.
Launching multiple stage Fragile X Syndrome pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Fragile X Syndrome market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Fragile X Syndrome Overview:
Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation(greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hyper methylated region in the gene promoter, therefore silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Also, FXS is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome.

Fragile X Syndrome Drugs Uptake and Pipeline Development Activities:

The drugs uptake section examines the adoption rate of newly launched or soon-to-be-launched drugs during the study period. It includes information on market uptake for each drug, patient adoption of therapies, and the sales performance of each drug. Furthermore, the report offers insights into the development activities for Fragile X Syndrome, evaluating therapeutic candidates at different stages and highlighting key companies involved.

For more information about Fragile X Syndrome companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Fragile X Syndrome Therapies and Key Companies:
Placebo: Zynerba Pharmaceuticals, Inc.
SPG601: Spinogenix
OV101 (gaboxadol): Ovid Therapeutics Inc.

Fragile X Syndrome Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Fragile X Syndrome.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Fragile X Syndrome Epidemiology Segmentation:
The Fragile X Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Fragile X Syndrome Total Prevalence
Fragile X Syndrome Prevalent Cases by severity
Fragile X Syndrome Gender-specific Prevalence
Fragile X Syndrome Diagnosed Cases of Episodic and Chronic

Fragile X Syndrome Market Drivers and Barriers:
The Fragile X Syndrome Market Forecast report highlights key drivers and barriers shaping the Fragile X Syndrome market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Fragile X Syndrome Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Fragile X Syndrome Companies: Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology
Key Fragile X Syndrome Therapies: ZYN002, Placebo, SPG601, OV101 (gaboxadol), BPN14770/ zatolmilast.
Fragile X Syndrome Therapeutic Assessment: Current marketed and emerging therapies
Fragile X Syndrome Market Dynamics: Fragile X Syndrome Market drivers and Fragile X Syndrome barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Fragile X Syndrome Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Fragile X Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:
1. Key Insights
2. Executive Summary of Fragile X Syndrome (FXS)
3. Competitive Intelligence Analysis for Fragile X Syndrome (FXS)
4. Fragile X Syndrome (FXS): Market Overview at a Glance
5. Fragile X Syndrome (FXS): Disease Background and Overview
6. Patient Journey
7. Fragile X Syndrome (FXS) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Fragile X Syndrome (FXS) Unmet Needs
10. Key Endpoints of Fragile X Syndrome (FXS) Treatment
11. Fragile X Syndrome (FXS) Marketed Products
12. Fragile X Syndrome (FXS) Emerging Therapies
List to be continued in report
13. Fragile X Syndrome (FXS): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Fragile X Syndrome (FXS)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fragile X Syndrome Market 2032, Insights by Delveinsight | Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics here

News-ID: 3651541 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Fragile

Fragile X Syndrome Fxs Treatment Market Size, Share & Trends [2035]
The Fragile X Syndrome Market Is Set To Grow At An Estimated CAGR Of 8.4% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $2.6 Billion By 2034. On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Fragile X Syndrome Fxs Treatment market goods. The market study excludes key regions that are
Fragile X-Syndrome Therapeutics Market: Treatment Strategies and Emerging Therap …
The Summary of the Fragile X-Syndrome Market Report The MMR offers a concise depiction of the "Fragile X-Syndrome Market" industry, delivering an in-depth analysis of the Fragile X-Syndrome market. It emphasizes standard subjects while tailoring data to suit specific requirements. This overview serves as a comprehensive guide for investors seeking insights into the current landscape of the Fragile X-Syndrome industry. Fragile X-Syndrome Market Expansion Fragile X-Syndrome Market size is expected to grow at
Sparkling Wine market status most fragile speculative growth trends
A new statistical surveying study titled Sparkling Wine Market investigates a few critical features identified with Sparkling Wine Market covering industry condition, division examination, and focused scene. Down to earth ideas of the market are referenced in a straightforward and unassuming way in this report. A far-reaching and exhaustive essential investigation report features various actualities, for example, improvement factors, business upgrade systems, measurable development, monetary benefit or misfortune to support
IT Education and Training MARKET STATUS – MOST FRAGILE & SPECULATIVE GROWTH TR …
” The newly added research report illustrating details on global IT Education and Training market delivers key insights on specific market elements such as competition intensity, regional growth opportunities, vendor profiles and requisite understanding of most potential growth triggers and vendor activities that harbinger growth in global IT Education and Training market. Crucial details on SWOT analysis, PESTEL analysis and Porter’s Five Forces analytical reviews have been professed with great
Life Sciences Software market status most fragile speculative growth trends
Detailed research added by Ample Market Research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Life Sciences Software market in the latest research report. The research study concisely dissects the Life Sciences Software and unearths valuable estimations pertaining to the profit projections, market size, sales capacity, and numerous other crucial parameters. Also, the Life Sciences Software Market report appraises the industry fragments
Fragile X Syndrome-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome-Pipeline Review, H2 2018, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay